At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,430 enrolled
Drug / intervention
Viviantdrug
Likely dose
Viviant 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post Marketing Surveillance For General Drug Use To Assess The Safety And Efficacy Profile Of Viviant In Usual Practice.
In Brief
An observational study evaluating Viviant for Osteoporosis. Completed, enrolled 3,430 participants across 60 sites.
Detailed Summary
This survey is conducted for preparing application material for re examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, and assessing the safety and efficacy profiles of VIVIANT in usual practice according to the Re-examination Regulation for New Drugs
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 2013
Enrollment StartOct 2013
Primary CompletionMay 2017
TodayJul 2026
First PostedFeb 15, 2013
Enrollment StartOct 24, 2013
Primary CompletionMay 31, 2017
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 13.4 years ago
Interventions
Viviantdrug
Viviant (Bazedoxifene) 20mg once daily